CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.
Friday, September 18, 2026
Published in Journal for immunotherapy of cancer. Abstract: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but can cause serious immune-related adverse events, with pneumonitis (ICI-P) being among the most severe. Early identification of high-risk patients before ICI initiation is critical for close monitoring, timely intervention, and optimizing outcomes. To develop and validate a deep learning foundation model to predict ICI-P from baseline CT scans in patients with lung cancer. We designed the Checkpoint-Inhibitor Pneumonitis Hazard EstimatoR (CIPHER), a deep learning-powered foundation model combining contrastive learning with a transformer-based masked autoencoder to predict ICI-P from baseline CT scans in patients with lung cancer. Using self-supervised learning, CIPHER was pretrained on 590,284 CT slices from 2,500 patients with non-small cell lung cancer (NSCLC) to learn representations of heterogeneous lung parenchyma. Following pretraining, CIPHER was adapted to the internal MD Anderson Cancer Center NSCLC immunotherapy cohort of 347 patients, of whom 33 developed adjudicated ICI-P. Fine-tuning was performed using 254 non-ICI-P patients only, and a held-out internal validation set of 93 patients, including 33 ICI-P cases and 60 non-ICI-P controls, was reserved for evaluation. CIPHER was benchmarked against clinical, radiomics, and ensemble comparator models and externally validated in an independent Johns Hopkins NSCLC cohort of 116 patients, including 20 ICI-P cases and 96 non-ICI-P controls. In our...
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. No account needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.